A phase i study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas

Clinical Cancer Research

Volumn 22, Issue 23, 2016, Pages 5696-5705

  Infante, Jeffrey R ^a   Cassier, Philippe A ^b   Gerecitano, John F ^c   Witteveen, Petronella O ^d   Chugh, Rashmi ^e   Ribrag, Vincent ^f   Chakraborty, Abhijit ^g   Matano, Alessandro ^h   Dobson, Jason R ^g   Crystal, Adam S ^g   Parasuraman, Sudha ^g   Shapiro, Geoffrey I ⁱ  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b CENTRE LÉON BÉRARD   (France)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF MICHIGAN   (United States)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; KI 67 ANTIGEN; RETINOBLASTOMA PROTEIN; RIBOCICLIB; AMINOPYRIDINE DERIVATIVE; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; PURINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; COLON CANCER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIMIT OF QUANTITATION; LIPOSARCOMA; LUNG EMBOLISM; LYMPHOCYTOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; QT PROLONGATION; RECOMMENDED DOSE FOR EXPANSION; SARCOMA; SIDE EFFECT; SKIN BIOPSY; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR BIOPSY; VOMITING; ANTAGONISTS AND INHIBITORS; BAYES THEOREM; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFECTS; METABOLISM; MIDDLE AGED; NEOPLASM; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AMINOPYRIDINES; BAYES THEOREM; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; PURINES; YOUNG ADULT;

EID: 85006293225     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1248     Document Type: Article

References (17)

1. Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov 2015;6:353-67.
2. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-83.
3. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002;1602:73-87.
4. Baker SJ, Reddy EP. CDK4: a key player in the cell cycle, development, and cancer. Genes Cancer 2012;3:658-69.
5. Zhang YX, Sicinska E, Czaplinski JT, Remillard SP, Moss S, Wang Y, et al. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Mol Cancer Ther 2014;13: 2184-93.
6. Liggett WH Jr, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998;16:1197-206.
7. Kim S, Loo A, Chopra R, Caponigro G, Huang A, Vora S, et al. LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6- reactivating rb in cancer. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia, PA: AACR; 2013. Abstract nr PR02.
8. Rader J, Russell MR, Hart LS, NakazawaMS, Belcastro LT, Martinez D, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res 2013;19:6173-82.
9. O'Brien N, Di Tomaso E, Ayala R, Tong L, Issakhanian S, Linnartz R, et al. Invivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CL. Philadelphia (PA): AACR; 2014. Abstract nr 4756.
10. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 2008;27:2420-39.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
12. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria formalignant lymphoma. J Clin Oncol 2007; 25:579-86.
13. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015;14:130-46.
14. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptorpositive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015;16:25-35.
15. Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015; 373:209-19.
16. Dickson MA, Tap WD, Keohan ML, D'Angelo SP, Gounder MM, Antonescu CR, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 2013;31:2024-8.
17. Vaughn DJ, Hwang WT, Lal P, Rosen MA, Gallagher M, O'Dwyer PJ. Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors. Cancer 2015;121:1463-8.